Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by (c) Ciruela and Jacobson, 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/171593

Editorial: Purinergic Pharmacology

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

The purine nucleotides and nucleosides constitute important extracellular signaling molecules acting as neurotransmitters and neuromodulators. Indeed, extracellular adenosine 5′-triphosphate (ATP) and adenosine, tightly controlled by nucleotidases, ribokinases, deaminases, and transporters, signal through a rich array of purinergic receptors. These receptors, which emerged early in evolution, are among the most abundant in living organisms controlling many physiological actions, thus becoming promising therapeutic targets in a wide range of pathological conditions. Thus, while P1 receptors are selective for adenosine, a breakdown product of ATP, P2 receptors are activated by purine nucleotides, as well as P2Y receptors being activated by pyrimidine nucleotides. Interestingly, purinergic receptors, both G protein-coupled (i.e., P1 and P2Y) and ligand-gated ion channel (i.e., P2X) receptors, are involved in many neuronal and non-neuronal mechanisms, including pain, immune responses, exocrine and endocrine secretion, platelet aggregation, endothelial-mediated vasodilatation and inflammation, among others.

Matèries (anglès)

Citació

Citació

CIRUELA ALFÉREZ, Francisco, JACOBSON, Kenneth a.. Editorial: Purinergic Pharmacology. _Frontiers In Pharmacology_. 2019-01-23. Vol. 10, núm. 21. [consulta: 21 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/171593]

Exportar metadades

JSON - METS

Compartir registre